Dasatinib

Dasatinib was developed by Bristol-Myers Squibb as a response to the clinical problem of imatinib resistance in chronic myeloid leukemia. The discovery that single point mutations in the BCR-ABL kinase domain, particularly the T315I gatekeeper mutation and numerous other substitutions, could render imatinib ineffective in a significant proportion of CML patients created urgent demand for next-generation inhibitors with broader conformational coverage. Dasatinib (BMS-354825) was rationally designed to bind the ABL kinase in multiple conformational states, unlike imatinib which requires the inactive DFG-out conformation. The FDA granted accelerated approval in June 2006 for adults with CML or Ph+ ALL who had failed prior imatinib therapy, with full approval in 2010 following the DASISION trial demonstrating first-line superiority over imatinib in newly diagnosed CML-CP. Marketed as Sprycel by Bristol-Myers Squibb, dasatinib is categorized as a second-generation BCR-ABL TKI alongside nilotinib, though the two drugs have distinct resistance mutation coverage profiles, side effect signatures, and off-target kinase activities. Pediatric approval followed in 2017 for Ph+ ALL and CML. In 2015, a fundamental discovery by Zhu et al. recontextualized dasatinib as the first clinically approved drug with senolytic activity, transforming it from an oncology drug into a founding molecule of the aging biology field and triggering a new generation of clinical senolytic research programs that continue to expand rapidly.

Dasatinib inhibits BCR-ABL with approximately 325-fold greater potency than imatinib in cell-based assays. The primary mechanistic explanation is conformational: imatinib binds only the inactive (DFG-out) conformation of the ABL kinase domain, which requires the kinase activation loop to adopt a specific closed orientation. Kinase domain mutations such as Y253H, E255K, F359V, and others destabilize this inactive conformation, preventing imatinib docking without affecting the ability of the kinase to catalyze phosphotransfer. Dasatinib binds both the active (DFG-in) and inactive conformations, achieving high-affinity engagement regardless of which conformation is preferred by the mutant ABL domain. This dual-conformation mechanism overrides most imatinib-resistance mutations, with the single important exception of T315I (the gatekeeper mutation), where the isoleucine substitution creates a steric clash that prevents binding by both imatinib and dasatinib. Beyond BCR-ABL, dasatinib is one of the broadest-spectrum TKIs in clinical use: it inhibits all eight members of the SRC family (SRC, LCK, YES1, FYN, LYN, HCK, FGR, BLK) at single-digit nanomolar concentrations, as well as PDGFR-beta, KIT, EPHA2, and EPHB4. The broad SRC family inhibition is relevant to CML biology because SRC kinases cooperate with BCR-ABL to drive proliferation and survival in leukemic cells. The same SRC kinase activity that is a secondary anti-leukemic mechanism in CML treatment became the primary mechanism of senolytic activity when the biology of senescent cell survival was characterized.

The senolytic mechanism was discovered through an unbiased bioinformatics analysis of the transcriptome of senescent human fat cell progenitors (preadipocytes), which had been induced to senesce through ionizing radiation. Comparison of the senescent and normal preadipocyte transcriptomes revealed upregulation of a network of pro-survival genes that Zhu et al. termed the Senescent Cell Anti-Apoptotic Pathway (SCAP). Pathway analysis identified SRC family kinases, PI3K components, and BCL-2 family members as central nodes. Drug-target matching identified dasatinib as the agent best suited to disrupt the SRC kinase component of the SCAP, and quercetin as the agent best suited to target the BCL-xL and PI3K components that dasatinib could not address. The combination was validated in vitro: dasatinib selectively eliminated senescent fat cell progenitors at concentrations that did not cytotoxically damage non-senescent cells, providing the therapeutic window that defines a senolytic agent. In aged mice, D+Q treatment reduced fat depot mass, improved grip strength, increased treadmill exercise capacity, and extended remaining lifespan. The conceptual foundation for this work was the earlier demonstration by Baker et al. (Nature 2011) using the INK-ATTAC transgenic mouse model that pharmacogenetic clearance of p16-positive senescent cells delayed aging-associated phenotypes including cataracts, lordokyphosis, and muscle wasting. The first human clinical trials in IPF (Justice et al. 2019) and diabetic kidney disease (Hickson et al. 2019) validated that the senolytic concept translates to humans, with measurable reduction of senescent cell markers in tissue biopsies and improvement of physical function, triggering a rapid expansion of phase 2 trials across multiple age-related diseases.

Dasatinib has oral bioavailability of approximately 14 to 34 percent with substantial inter-patient variability driven by CYP3A4 first-pass metabolism and P-glycoprotein efflux. Its plasma half-life of 3 to 5 hours is short relative to its pharmacodynamic duration, as kinase receptor occupancy persists beyond plasma clearance, justifying once-daily oncology dosing. The most critical drug interaction is with gastric acid-suppressing medications: dasatinib requires acidic pH for dissolution, and PPIs reduce AUC by up to 78 percent, potentially rendering standard CML doses subtherapeutic. In oncology, the approved dose is 100 mg once daily for CML-CP; dose interruption and reduction to 80 mg are the primary tools for managing pleural effusion and myelosuppression. Longevity senolytic protocols employ radically different dosing from the continuous daily oncology regimen: most clinical protocols use 100 mg dasatinib plus 1,000 mg quercetin for 2 consecutive days per month, with cycles repeated monthly or every 3 months. This intermittent approach reflects the biology of senescent cell accumulation, which occurs slowly over months to years, such that brief pulse dosing is sufficient to clear recently accumulated senescent cells without the need for continuous drug exposure. The total lifetime exposure in a 12-cycle annual senolytic protocol is estimated at approximately 1 to 2 percent of the exposure incurred in continuous CML treatment, substantially improving the safety profile for the non-cancer longevity indication. Multiple phase 2 trials are now active in Alzheimer disease (MILES trial), myelodysplastic syndromes, post-COVID-19 conditions, frailty, osteoarthritis, and additional pulmonary and renal indications, with results expected to define the efficacy and long-term safety profile of intermittent D+Q senolytic therapy in diverse aging populations.

Mechanism of Action

BCR-ABL Kinase Inhibition and CML Biology

Chronic myeloid leukemia arises from a reciprocal chromosomal translocation between chromosomes 9 and 22, generating the Philadelphia chromosome and the BCR-ABL1 fusion gene. The BCR-ABL1 fusion protein is a constitutively active tyrosine kinase: the BCR coiled-coil domain causes dimerization that displaces the myristoylated N-terminal cap of ABL1, releasing the kinase from autoinhibition and producing continuous kinase activity uncoupled from physiological growth factor signals. This constitutively active kinase phosphorylates downstream substrates continuously, activating STAT5 (driving proliferation through cyclin D1 and c-Myc), the RAS/MAPK pathway (cell cycle progression), PI3K/AKT (survival and apoptosis resistance), and the FAK/paxillin pathway (reduced adhesion to stroma, enabling leukemic cell release into circulation). The resulting phenotype of the CML progenitor cell is one of rapid proliferation, resistance to apoptosis, and loss of normal hematopoietic regulatory responses, which collectively produce the characteristic leukocytosis and potential for blast transformation.

Imatinib (Gleevec, the first-generation BCR-ABL TKI) achieves inhibition by binding the inactive conformation of the ABL kinase domain, which requires the activation loop to adopt a closed, DFG-out orientation. The vulnerability of imatinib therapy is that single amino acid substitutions in the BCR-ABL kinase domain can stabilize the active conformation, preventing imatinib docking. Resistance mutations at Y253, E255, T315, F317, F359, and multiple other positions emerge in a proportion of patients, representing the principal mechanism of acquired imatinib resistance. Dasatinib overcomes this resistance by binding both the active and inactive conformations, achieving high-affinity engagement regardless of which conformation is stabilized by the mutation. Crystallographic evidence (Tokarski et al. 2006, PMID 16840698) confirmed that dasatinib occupies the active-conformation ATP binding site, consistent with the dual-binding model. The single exception is the T315I gatekeeper mutation, where the isoleucine substitution removes a critical threonine hydroxyl group that hydrogen-bonds with both imatinib and dasatinib, and the larger isoleucine side chain creates steric occlusion in the binding pocket; T315I confers resistance to all first- and second-generation TKIs and requires ponatinib (a third-generation TKI) or asciminib (an STAMP inhibitor) for management. The potency advantage of dasatinib (IC50 approximately 0.6 nM versus approximately 200 nM for imatinib against BCR-ABL) ensures that wild-type and most mutant BCR-ABL kinases are suppressed well below the threshold for signaling even at plasma trough concentrations achieved with once-daily dosing.

SRC Family Kinase Inhibition

The SRC family comprises eight closely related non-receptor tyrosine kinases: SRC, LCK, YES1, FYN, LYN, HCK, FGR, and BLK. These kinases share a conserved domain architecture consisting of an N-terminal SH4 domain, a unique region, an SH3 domain, an SH2 domain, a kinase (SH1) domain, and a C-terminal regulatory tail. The SH2 and SH3 domains mediate intramolecular autoinhibition by binding the phosphorylated C-terminal tail and the kinase linker, respectively; disruption of these autoinhibitory interactions by growth factor receptor signals, focal adhesion complexes, or activating mutations leads to kinase activation. In CML, SRC family members LYN and HCK are expressed in myeloid cells and cooperate with BCR-ABL to amplify survival and proliferation signals: BCR-ABL phosphorylates and activates LYN, which in turn phosphorylates BCR-ABL at additional sites, creating a positive feedback loop that amplifies the leukemogenic signal. The broad SRC family inhibition by dasatinib therefore disrupts this cooperative signaling in CML cells, adding to the direct BCR-ABL inhibition.

Dasatinib inhibits SRC family kinases at IC50 values of 0.5 to 3 nM, achieving essentially complete inhibition at the concentrations reached in plasma with oncology dosing. LCK inhibition is particularly relevant in the context of T-cell function: LCK is the primary kinase in the T-cell receptor signaling cascade, and its inhibition by dasatinib contributes to the lymphopenia (expanded large granular lymphocyte populations) and potentially immunomodulatory effects observed with long-term dasatinib treatment. The clinical implication is that dasatinib-treated CML patients may have altered immune responses, including effects on immune surveillance and vaccination responses. In the senolytic context, the SRC family inhibition is the primary mechanism: senescent cells express constitutively active SRC family kinases as part of their survival program, and these kinases are more critically required for senescent cell survival than for normal cell survival.

Senescent Cell Anti-Apoptotic Pathway (SCAP) Disruption

Cellular senescence is a state of permanent cell cycle arrest that develops in response to DNA damage, oncogenic stress, replicative exhaustion, or other cellular insults. While initially a tumor-suppressive response preventing damaged cells from proliferating, senescent cells that persist in tissues cause damage through their SASP. The SASP includes dozens of pro-inflammatory cytokines, chemokines, matrix metalloproteinases, and growth factors that collectively degrade the extracellular matrix, recruit inflammatory cells, and induce senescence in neighboring normal cells through paracrine mechanisms. Senescent cells resist apoptosis despite being metabolically active and transcriptionally busy, through a network of pro-survival signals that Zhu et al. termed the Senescent Cell Anti-Apoptotic Pathway.

The SCAP includes multiple pro-survival mechanisms: SRC-PI3K-AKT-BCL-xL, BCL-2 and BCL-W family member upregulation, p21-mediated caspase inhibition, HSP90 chaperone activity, and FOXO4-p53 nuclear sequestration (preventing p53 from triggering mitochondrial apoptosis). The specific SCAP components expressed vary by senescent cell type. In senescent fat cell progenitors, the dominant survival component is the SRC kinase axis: SRC, YES1, and LYN are constitutively active in senescent preadipocytes and maintain AKT phosphorylation and BCL-xL expression in the absence of growth factor receptor signals. Normal preadipocytes have low-level SRC activity that is growth-factor-coupled; when growth factor signaling is absent, they do not maintain high-level AKT or BCL-xL activity and are susceptible to apoptosis by default. The constitutive, growth-factor-uncoupled nature of SRC activity in senescent cells is the mechanistic basis for the selectivity of dasatinib as a senolytic: at concentrations that block the constitutive SRC activity in senescent cells, normal cells (which have minimal uncoupled SRC activity) retain adequate survival signaling through growth-factor-coupled pathways that dasatinib does not block. Downstream of SRC inhibition, AKT phosphorylation falls, BCL-xL expression declines, and the threshold for intrinsic apoptosis (cytochrome c release from mitochondria, caspase-9 and caspase-3 activation) drops to the point where the modest levels of DNA damage present in senescent cells become sufficient to trigger apoptotic cell death.

The therapeutic selectivity in cell-based assays was confirmed by Zhu et al. (2015): dasatinib at 100 nM reduced the number of senescent fat cell progenitors by approximately 50 percent within 48 hours while having no significant effect on non-senescent fat cell progenitors at the same concentration. Quercetin complemented this action by targeting a partially overlapping but distinct SCAP architecture in senescent endothelial cells and other cell types, providing the rationale for the combination protocol.

Broad Kinase Profile: PDGFR, KIT, and Ephrin Receptors

Beyond BCR-ABL and the SRC family, dasatinib inhibits several additional receptor tyrosine kinases with clinical implications in specific contexts. PDGFR-beta (platelet-derived growth factor receptor beta) is inhibited at concentrations achievable with standard dosing, contributing potential anti-fibrotic effects through reduced activation of fibroblast and pericyte proliferation pathways that PDGF signaling drives. This PDGFR-beta inhibition may be relevant to the therapeutic activity of dasatinib in IPF, where PDGF-driven fibroblast activation is a component of the fibrotic process, complementing the senolytic mechanism of p16-positive fibroblast elimination. KIT (c-Kit, CD117) inhibition by dasatinib is relevant in the context of certain mast cell disorders and gastrointestinal stromal tumors (GISTs), though dasatinib is not primarily used for these indications. Ephrin receptor inhibition (EPHA2, EPHB4) contributes to anti-invasive effects through disruption of cell-cell contact-mediated signaling. The antiplatelet effect of dasatinib through SRC family kinase inhibition in platelets (LYN and FYN are key mediators of platelet collagen receptor signaling) is a pharmacodynamic consequence that is pharmacologically relevant when dasatinib is combined with anticoagulants or antiplatelet agents.

Transcriptional and Epigenetic Context of Senescent Cell Survival

Senescent cells maintain their pro-survival phenotype through sustained transcriptional programs reinforced by epigenetic changes. The SASP is driven largely by NF-kappaB and C/EBPbeta transcription factors that are constitutively active in senescent cells through upstream DAMP (damage-associated molecular pattern) and cytokine signaling. Senescent cells also acquire characteristic histone modifications including loss of H3K27me3 (Polycomb repressive complex target silencing) at SASP gene loci, allowing their sustained transcription. mTORC1 activity, which is often elevated in senescent cells, promotes SASP translation through S6K1 and 4E-BP1. The FOXO4-p53 nuclear complex, discussed in the geneInteractions section, is an additional senescent-cell-specific transcriptional and survival mechanism. Dasatinib, by eliminating senescent cells entirely rather than suppressing their SASP, removes all these transcriptional programs simultaneously, in contrast to senomorphic agents (metformin, rapamycin, ruxolitinib) that suppress SASP while leaving the senescent cells alive to potentially resume SASP secretion if the senomorphic drug is discontinued.

Clinical Evidence

DASISION: First-Line CML-CP

The DASISION (Dasatinib versus Imatinib Study In treatment-Naive CML patients) trial was an international, randomized, phase 3 study that enrolled 519 patients with newly diagnosed CML in chronic phase and randomized them to dasatinib 100 mg once daily versus imatinib 400 mg once daily. The primary endpoint was confirmed complete cytogenetic response (CCyR, defined as 0 percent Philadelphia chromosome-positive metaphases in bone marrow) at 12 months. At 12 months, CCyR was achieved in 77 percent of dasatinib patients versus 66 percent of imatinib patients (p=0.007), and major molecular response (MMR, BCR-ABL ratio below 0.1 percent on the international scale) was achieved in 46 versus 28 percent (p less than 0.0001). The time to CCyR was significantly shorter with dasatinib (median 5.6 versus 10.2 months). Progression to accelerated phase or blast crisis occurred in 1.9 percent of dasatinib patients versus 3.5 percent of imatinib patients at 12 months, a difference that did not reach statistical significance at this early time point but was consistent with the hypothesis that faster, deeper responses reduce transformation risk.

The 5-year follow-up of DASISION (Cortes et al., JCO 2016, PMID 26819062) confirmed that the deep molecular response advantage with dasatinib was maintained and widened over time. MR4.5 (BCR-ABL ratio below 0.0032 percent) was achieved in 26 percent of dasatinib patients versus 18 percent of imatinib patients at 5 years. Overall survival was not significantly different between arms at 5 years (91 versus 90 percent), partly because patients who progressed on one TKI were offered effective salvage therapy with other agents. The key clinical implication of the deeper early molecular responses with dasatinib is an increased likelihood of achieving treatment-free remission eligibility. Current European LeukemiaNet guidelines recommend second-generation TKIs including dasatinib as first-line options alongside imatinib, with the choice informed by comorbidities, risk score, and TFR aspiration.

Imatinib-Resistant CML and Ph+ ALL

The original dasatinib approval was based on trials in imatinib-resistant or imatinib-intolerant CML and Ph+ ALL. In imatinib-resistant CML-CP patients, dasatinib produced CCyR in approximately 50 percent and MMR in approximately 40 percent, including patients who had acquired most BCR-ABL kinase domain mutations. The exception to dasatinib activity in the resistance setting is the T315I gatekeeper mutation, which accounted for approximately 15 to 20 percent of imatinib-resistant cases in large series. In Ph+ ALL, the combination of dasatinib with chemotherapy induction produces complete hematologic response rates exceeding 90 percent. The CNS penetration advantage of dasatinib over imatinib (approximately 3-fold higher CSF concentrations in clinical pharmacokinetic studies) is a clinically meaningful differentiator in Ph+ ALL, where CNS sanctuary relapse is a significant concern. The dasatinib-based induction approach for Ph+ ALL is now standard at many centers, with deeper molecular responses and potential for less intensive chemotherapy backbones in older or frail patients who cannot tolerate hyperCVAD.

Preclinical Senolytics Discovery

The conceptual foundation for dasatinib as a senolytic rests on two seminal studies. Baker et al. (Nature 2011, PMID 21720395) used the INK-ATTAC transgenic mouse model to demonstrate for the first time that pharmacogenetic clearance of p16(INK4a)-positive cells starting at middle age delayed the onset of age-associated phenotypes including cataracts, lordokyphosis, and muscle wasting, and that clearance starting after phenotypes were established could partially reverse them. This study proved that senescent cells are a causal driver of aging-associated pathology rather than merely a correlation, establishing the therapeutic hypothesis. Five years later, Zhu et al. (Aging Cell 2015, PMID 25754370) provided the pharmacological translation: they identified the SCAP network through transcriptomic analysis of senescent preadipocytes, computationally matched SCAP nodes to FDA-approved drugs, and validated dasatinib and quercetin as the first pharmacological senolytic combination. In aged mice, D+Q treatment eliminated approximately 30 percent of senescent cells in fat deposits, improved grip strength and exercise capacity, and extended remaining median lifespan by approximately 36 percent when treatment began late in life. Subsequent studies in multiple additional mouse models confirmed the senolytic activity in tissues beyond adipose, including lung, liver, kidney, and bone marrow, establishing the cross-tissue generalizability that underpins the current clinical trial programs.

First Human Senolytic Trials: IPF and Diabetic Kidney Disease

The translational step from mouse to human was accomplished through two near-simultaneous pilot trials published in 2019, both exploiting disease states with well-characterized senescent cell pathology. Justice et al. (EBioMedicine 2019, PMID 30616949) enrolled 14 patients with idiopathic pulmonary fibrosis, a disease where senescent alveolar epithelial type II cells and fibroblasts are histologically and molecularly confirmed. Two cycles of D+Q (dasatinib 100 mg plus quercetin 1,000 mg for 3 consecutive days each, separated by 3 weeks) were administered. Physical function improved: 6-minute walk distance increased by a mean of 21 meters, gait speed improved by 0.04 m/s, chair-stand time decreased, and stair climbing speed increased, all changes that are clinically meaningful in a population where even stable disease represents deterioration. Circulating SASP factors including MMP-7 (a clinically validated biomarker of IPF disease activity), IL-6, TNFRSF1A, and ICAM-1 declined significantly. The absence of a placebo arm and the small sample size limit causal inference, but the biological specificity of the SASP changes and the clinical plausibility of the physical function improvements establish this as the first human proof-of-concept for senolytic therapy.

Hickson et al. (EBioMedicine 2019, PMID 31164344) addressed the limitation of plasma-only biomarkers by obtaining tissue biopsies. Nine patients with diabetic kidney disease received three cycles of D+Q (100 mg plus 1,000 mg for 2 days per week over 3 consecutive weeks). Adipose and skin biopsies taken at baseline and at the end of treatment showed reductions in p16(INK4a)-positive cell density (assessed by immunohistochemistry) and in p21-positive cell density, with statistical significance in both tissues. Plasma SASP factor profiling confirmed reductions in IL-1alpha, IL-6, MMP-9, and a composite senescence activation score. The tissue-level histological confirmation is a methodological advance over plasma biomarker studies because it directly visualizes the senescent cell populations being targeted, providing a direct mechanistic link between D+Q treatment and cellular-level senescence clearance in human disease tissue.

Ongoing Senolytic Clinical Trials

Multiple phase 2 trials are now testing D+Q and related senolytic regimens across a spectrum of age-related conditions. The MILES (Mayo Investigation of LEvels of Senolytics) trial is evaluating D+Q in early Alzheimer disease, with cognitive outcomes and CSF biomarkers of neuroinflammation as primary endpoints. Additional active trials include studies in myelodysplastic syndrome, osteoarthritis, age-related macular degeneration, frailty in older adults, post-COVID-19 conditions, and chronic low back pain with imaging-confirmed disc degeneration. The therapeutic hypothesis in each case is that reducing senescent cell burden and SASP will reduce the inflammatory and tissue-damaging contributions of these cells to disease progression. The FDA has granted Breakthrough Therapy designation to senolytic approaches in IPF, reflecting regulatory acknowledgment of the mechanistic plausibility and unmet medical need in that indication. Results from these trials, expected over the next 2 to 5 years, will define whether the functional benefits observed in IPF and DKD pilots generalize across the spectrum of senescence-driven diseases.

Adverse Effects in Long-Term Trials

The 5-year DASISION safety data provide the most comprehensive long-term safety characterization of dasatinib at the 100 mg once-daily oncology dose. Pleural effusion was the most common serious adverse event, occurring in 28 percent of dasatinib patients over 5 years (versus 0.8 percent with imatinib). The mechanism is endothelial injury and increased vascular permeability secondary to PDGFR-beta and SRC kinase inhibition in the pleural microvasculature. Grade 3-4 pleural effusion occurred in 5 percent of patients and required dose reduction or interruption plus management with diuretics and corticosteroids; pleural effusion resolved without permanent discontinuation in most cases. Pulmonary arterial hypertension was identified as a rare but serious adverse event occurring in approximately 0.4 to 1 percent of CML patients on long-term dasatinib, typically after 12 to 24 months of continuous therapy; the mechanism involves endothelial dysfunction and pulmonary vascular remodeling triggered by sustained PDGFR-beta and SRC inhibition in pulmonary vascular smooth muscle and endothelial cells. PAH may require permanent discontinuation and treatment with pulmonary vasodilators (phosphodiesterase-5 inhibitors, endothelin receptor antagonists). Myelosuppression required dose interruption in approximately 40 percent of patients over 5 years, reflecting the expected hematopoietic toxicity of a drug that inhibits BCR-ABL-related signaling in progenitor cells. QTcF prolongation above 500 ms or by more than 60 ms from baseline occurred in fewer than 2 percent of patients.

The toxicity profile at senolytic doses (2 days per month rather than continuous daily) is expected to be substantially more favorable than the CML profile, with the total drug exposure from a 12-cycle annual protocol being approximately 24 days of exposure versus 365 days of continuous CML dosing. Early senolytic pilot trials have not reported clinically significant pleural effusion or PAH at the low-dose intermittent schedule, though the sample sizes are too small to characterize rare adverse events. The key safety concerns at senolytic doses are transient cytopenias (reversible within 1 to 2 weeks given the short exposure), QT effects from the 2-day pulse, and potential drug interactions particularly with antacids and QT-prolonging co-medications.

Longevity and Off-Label Evidence

The longevity application of dasatinib is entirely in the off-label senolytic context, as no FDA indication for dasatinib covers non-malignant indications. The rationale for intermittent dosing rests on two biological principles: senescent cells accumulate slowly (over months to years in most tissues), so periodic clearance is biologically rational; and the elimination of a senescent cell is durable until that cell is replaced by a new senescent cell, meaning that the anti-SASP benefit of a treatment cycle persists for weeks to months after the drug is cleared. The most commonly referenced senolytic protocol uses 100 mg dasatinib plus 1,000 mg quercetin for 2 consecutive days per cycle, with cycles repeated monthly or every 3 months. The choice of 2 days (versus the 3 days used in the IPF trial) reflects the shorter duration being judged sufficient to achieve senescent cell clearance while minimizing the myelosuppression risk from cumulative exposure. No randomized clinical trial has yet compared different senolytic dosing schedules in terms of efficacy or safety.

The existing human trial data (IPF pilot and DKD pilot) are the only published clinical evidence for D+Q in a longevity or disease prevention context. Both used patient populations with established disease and known senescent cell pathology, rather than healthy aging individuals using D+Q as a preventive intervention. The extrapolation from established-disease pilot data to healthy-aging prevention is biologically plausible but clinically unvalidated: the magnitude of senescent cell burden in a healthy 50-year-old is substantially lower than in IPF or DKD patients, and the effect size of D+Q may be correspondingly smaller. The long-term safety of repeated senolytic cycling over years in a healthy non-cancer population has not been studied. Until phase 2 trial data in aging populations are available, the risk-benefit calculation for senolytic use in healthy individuals remains speculative, despite the compelling preclinical biology.

Dasatinib versus Nilotinib: Second-Generation TKI Comparison

Dasatinib and nilotinib are the two approved second-generation BCR-ABL TKIs used in first-line CML treatment, and their distinct pharmacological profiles lead to different clinical use cases. Nilotinib is more selective for BCR-ABL and related kinases (PDGFR-alpha, KIT) with minimal SRC kinase activity, whereas dasatinib has broad SRC family inhibition. This kinase selectivity difference translates into distinct toxicity profiles: nilotinib is associated with cardiovascular adverse events including peripheral artery disease, coronary artery disease, and metabolic syndrome (hyperglycemia, elevated lipids), whereas dasatinib causes pleural effusion and pulmonary arterial hypertension. These toxicity differences create patient-specific treatment choices: patients with pre-existing cardiovascular disease, diabetes, or high cardiovascular risk are better served by dasatinib; patients with pre-existing pleural or pulmonary disease favor nilotinib. In terms of BCR-ABL mutation coverage, dasatinib retains activity against F317L (nilotinib-resistant) while nilotinib covers Y253H and E255K better (some dasatinib activity but reduced relative to nilotinib). CNS penetration strongly favors dasatinib, making it the preferred second-generation TKI for patients with CNS involvement or Ph+ ALL. For deep molecular response rates supporting treatment-free remission attempts, both drugs produce similar proportions of patients achieving MR4.5 at 5 years in their respective registration trials. Bosutinib represents a third second-generation option with a distinct kinase profile (SRC and ABL but not KIT/PDGFR), offering an alternative for patients who develop toxicity to dasatinib or nilotinib.

Dosing Guidance

The FDA-approved dose for CML-CP is 100 mg once daily, and this dose should not be exceeded for new patient starts or for patients without documented resistance to lower doses. For CML-AP/BP and Ph+ ALL, the approved dose is 140 mg once daily. Dose reduction for grade 3-4 toxicity follows a stepwise approach: first reduction to 80 mg once daily, second reduction to 50 mg once daily, with permanent discontinuation considered if the drug cannot be tolerated at 50 mg. Dose increases above 100 mg for CML-CP are not recommended in current guidelines despite early phase studies using higher doses. For pediatric patients, dosing is weight-based (approximately 60 to 80 mg/m2 once daily) using either tablets or oral solution depending on age and swallowing ability.

For longevity senolytic protocols, the most studied and referenced regimen is dasatinib 100 mg once daily plus quercetin 1,000 mg (divided across the day as three 333 mg doses) for 2 consecutive days per cycle, with cycles repeated monthly for 6 to 12 months, then a reassessment period. Quercetin is often taken with breakfast, lunch, and dinner to space the doses across the day. The acid suppression interaction is less clinically critical at the 2-day senolytic dose than at continuous oncology dosing, but avoidance of proton pump inhibitors on the 2 treatment days is still prudent to ensure adequate dasatinib absorption. Patients using the senolytic protocol should not take antacids within 2 hours of the dasatinib dose on either treatment day. CBC monitoring 1 to 2 weeks after each cycle is recommended for the first several cycles to characterize individual myelosuppression susceptibility, with monitoring frequency potentially reduced after a consistent tolerability profile has been established.